US 11,938,122 B2
5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
Maria Pilar Pizcueta Lalanza, Barcelona (ES); and Marc Martinell Pedemonte, Barcelona (ES)
Assigned to Minoryx Therapeutics S.L., Barcelona (ES)
Appl. No. 16/465,043
Filed by Minoryx Therapeutics S.L., Mataró Barcelona (ES)
PCT Filed Dec. 1, 2017, PCT No. PCT/IB2017/057587
§ 371(c)(1), (2) Date May 29, 2019,
PCT Pub. No. WO2018/100557, PCT Pub. Date Jun. 7, 2018.
Claims priority of application No. 16382584 (EP), filed on Dec. 1, 2016.
Prior Publication US 2020/0093812 A1, Mar. 26, 2020
Int. Cl. A61K 31/4439 (2006.01); A61K 9/08 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 9/08 (2013.01); A61K 9/16 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61P 1/16 (2018.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating nonalcoholic fatty liver disease, comprising administering to a subject in need thereof a dosage form comprising an effective amount of a compound of formula (1)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis.